Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri,[1] Max Nievaart,[1] William Perkin,[1] Amy Zalin-Miller,[2] Craig Knott,[2] and Simran Gill[1*]

[1]Johnson & Johnson Innovative Medicine, High Wycombe, United Kingdom; [2]Health Data Insight CIC, Fulbourn, United Kingdom and National Disease Registration Service (NDRS), United Kingdom

**Presenting author*

Click anywhere to view this interactive poster

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

KEY TAKEAWAY

There is an urgent unmet need for newer treatments in the first and second-line settings to improve survival outcomes for mUC patients in England

mUC, Metastatic urothelial carcinoma.

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS
Study Population
RESULTS
Patient Outcomes 1
RESULTS
Patient Outcomes 2
RESULTS
Patient Outcomes 3
LIMITATIONS
APPENDIX

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

CONCLUSIONS

- A high attrition rate in SACT was observed with 63% of patients untreated from 2016-2021 followed up to 2023
- The median OS was 5.4 months from diagnosis indicating a poor prognosis
- Further real-world studies to explore the reasons behind poor survival in bladder cancer are required; underscoring the importance of a national bladder cancer audit

OS, Overall survival; SACT, Systemic anti-cancer treatment.

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS Study Population
RESULTS Patient Outcomes 1
RESULTS Patient Outcomes 2
RESULTS Patient Outcomes 3
LIMITATIONS
APPENDIX

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

INTRODUCTION

- In England, platinum-based chemotherapy with or without an immune checkpoint inhibitor is the standard-of-care for patients diagnosed with mUC
- However, treatment patterns following first-line therapy and outcomes in patients diagnosed with mUC remain unclear given the national clinical guidelines are outdated following recent marketing authorisations of medicines in mUC
- There is a need to collect real-world data to enable an improved understanding of the clinical management of mUC in the NHS and associated outcomes

mUC, Metastatic urothelial carcinoma; NHS, National health service.

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS Study Population
RESULTS Patient Outcomes 1
RESULTS Patient Outcomes 2
RESULTS Patient Outcomes 3
LIMITATIONS
APPENDIX

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

OBJECTIVES

- Retrospectively identify and follow-up patients diagnosed with mUC in England to provide insight into real-world clinical practice
- Describe the baseline characteristics and distribution of patients diagnosed with mUC in England by:
  - Lines of systemic anti-cancer therapy and
  - Treatment with prior anti-PD-(L)1 therapy to understand the patient treatment pathway in England
- Report a key treatment milestone, mainly OS, from the date of diagnosis and the initiation of subsequent systemic anti-cancer therapy

Anti-PD-(L)1 , Anti programmed death-ligand 1; mUC, Metastatic urothelial carcinoma; OS, Overall survival.

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS Study Population
RESULTS Patient Outcomes 1
RESULTS Patient Outcomes 2
RESULTS Patient Outcomes 3
LIMITATIONS
APPENDIX

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

METHODS

Data sources:

- Routine patient data was obtained through the NDRS, which collects data from all patients diagnosed with cancer in England. Diagnoses were extracted for the period from January 2016 to December 2021, with follow-up to March 2023 to report treatment and progression

Variables:

- Patient baseline demographics, tumour characteristics, SACT and lines of treatment were obtained

Outcomes:

- Distribution of patients by line of therapy
- Kaplan-Meier methods were used to calculate OS

NDRS, National Disease Registration Service; OS, Overall survival; SACT, Systemic anti-cancer therapy.

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS Study Population
RESULTS Patient Outcomes 1
RESULTS Patient Outcomes 2
RESULTS Patient Outcomes 3
LIMITATIONS
APPENDIX

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

RESULTS

Study population

- A total of 10,787 patients were diagnosed with mUC between January 2016 and December 2021 (**Table 1**)
- 3,942 patients (37%) of patients received SACT
- 1,376 mUC patients received an anti-PD-(L)1 treatment
- The mean age at diagnosis was 74 years (median 75 years)
- Male patients comprised 66% of the overall cohort
- Patients who received an anti-PD-(L)1 treatment were younger with mean age at diagnosis of 69 years (median 70 years)
- Of patients with a known PS, a higher proportion of patients who received an anti-PD-(L)1 had a PS of 0-1 compared to the overall cohort

Table 1: Baseline characteristics

Characteristic	All patients N=10,787	PD-(L)1 exposed N=1,376
Age in years, median (IQR)	75.0 (68.0–82.0)	70.0 (63.0-76.0)
Age category at diagnosis, n (%)		
18 to 34	21 (0.2)	5 (0.4)
35 to 49	275 (2.5)	59 (4.3)
50 to 64	1,657 (15.4)	333 (24.2)
65 and older	8,834 (81.9)	979 (71.1)
Male, n (%)	7,115 (66.0)	985 (71.6)
Year of initial diagnosis, n (%)		
2016	2,202 (20.4)	156 (11.3)
2017	2,458 (22.8)	295 (21.4)
2018	1,756 (16.3)	312 (22.7)
2019	1,353 (12.5)	185 (13.4)
2020	1,565 (14.5)	220 (16.0)
2021	1,453 (13.5)	208 (15.1)
Performance status at diagnosis, n (%)		
0	1,780 (16.5)	380 (27.6)
1	1,296 (12.0)	209 (15.2)
2	578 (5.4)	34 (2.5)
3	359 (3.3)	5 (0.4)
4	77 (0.7)	1 (0.1)
Null	6,697 (62.1)	747 (54.3)
Cisplatin ineligibility at diagnosis, n (%)		
Yes	3,409 (31.6)	341 (24.8)
No	7,378 (68.4)	1,035 (75.2)
Duration of follow-up from diagnosis		
Mean (standard deviation), months	11.8 (16.5)	16.9 (14.6)
Median (Q1–Q3)	5.3 (1.9-14.1)	12.6 (6.6-22.0)

Anti-PD-(L)1, Anti programmed death-ligand 1; IQR, Interquartile range; mUC, Metastatic urothelial carcinoma; N, Count; PS, Performance status; Q, Quartile; SACT, Systemic anti-cancer therapy; %, Proportion.

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS Study population
RESULTS Patient Outcomes 1
RESULTS Patient Outcomes 2
RESULTS Patient Outcomes 3
LIMITATIONS
APPENDIX

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

RESULTS

- **High attrition rates (Table 2 and Figure 1):**
  - 37% of 10,787 patients received a first-line treatment
  - 24% of 3,942 patients received a second-line treatment

Figure 1: SACT attrition rates



SACT, Systemic anti-cancer therapy.
Note: Denominator is 3,942 (patients receiving a line of therapy)

Table 2: SACT delivery among patients with mUC

Incident 'metastatic' cancer patients with derived lines of therapy, N (%)	**3,942 (36.5)**
Received at least one drug from the following classes and regimens, N (%)	
Alkylating agents	26 (0.7)
Anthracyclines	35 (0.9)
Antimetabolites	2,979 (75.6)
Cytotoxic antibiotics	129 (3.3)
Hormone treatments	18 (0.5)
Immune checkpoint inhibitors	1,376 (34.9)
Atezolizumab	563 (40.9)
Avelumab	147 (10.7)
Pembrolizumab	668 (48.5)
Immunomodulators	28 (0.7)
Monoclonal antibodies	12 (0.3)
Other cytotoxic agents	204 (5.2)
Platinum compounds	3,117 (79.1)
Targeted therapies	33 (0.8)
Taxanes	216 (5.5)
Patients who received 1L anti-PD-(L)1 therapy including maintenance avelumab	834 (7.7)
Common 2L regimens received following 1L anti-PD-(L)1 therapy, N (%)	
Carboplatin + Gemcitabine	47 (5.6)
Paclitaxel	30 (3.6)
Pembrolizumab	17 (2.0)
Atezolizumab	12 (1.4)
Patients who received 1L systemic therapy followed by 2L anti-PD-(L)1	515 (4.8)
Common 3L regimens received following 2L anti-PD-(L)1 therapy, N (%)	
Paclitaxel	24 (4.7)
Pembrolizumab	14 (2.7)
Carboplatin + Paclitaxel	12 (2.3)
Patients who received 1L platinum-based therapy with maintenance avelumab	127 (1.2)
Common 2L regimens received following 1L platinum-based therapy with avelumab, N (%)	
Paclitaxel	10 (7.9)

Anti-PD-(L)1 , Anti programmed death-ligand 1; 1L, First-line; mUC, Metastatic urothelial carcinoma; N, Number; SACT, Systemic anti-cancer therapy; 2L, Second-line; 3L, Third line; %, Proportion. Note: 27 patients received anti-PD-(L)1 at 3L+

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS Study Population
RESULTS Patient Outcomes 1
RESULTS Patient Outcomes 2
RESULTS Patient Outcomes 3
LIMITATIONS
APPENDIX

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

RESULTS

- **Standard-of-care (Table 2)**
  - Significant use of anti-PD-(L)1 inhibitors in the 1L setting
  - 5.6% of patients received carboplatin + gemcitabine driven by temporary COVID guidance[1]
  - 2L and subsequent treatment after anti-PD-(L)1 is predominantly paclitaxel monotherapy or paclitaxel in combination with carboplatin
- **Poor prognosis (Table 3 and Figure 2)**
  - Median OS of 5.4 months for mUC patients from diagnosis
  - Median OS of 7 months for mUC patients on 2L and 3L treatments

Figure 2: Kaplan-Meier curves showing OS from the date of diagnosis and from the initiation of 1L, 2L and 3L+ SACT



Anti-PD-(L)1, Anti programmed death-ligand 1; COVID, Coronavirus disease of 2019; 1L, First-line; mUC, Metastatic urothelial carcinoma; OS, Overall survival; SACT, Systemic anti-cancer therapy; 2L, Second-line; 3L, Third line.

1. NHS England. NHS England interim treatment options during the COVID-19 pandemic. 2021, https://www.theacp.org.uk/userfiles/file/resources/covid_19_resources/nhs-england-interim-treatment-options-during-the-covid19-pandemic-pdf-8715724381-6-jan-2021.pdf (accessed June 2024).

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS Study Population
RESULTS Patient Outcomes 1
RESULTS Patient Outcomes 2
RESULTS Patient Outcomes 3
LIMITATIONS
APPENDIX

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

RESULTS

Table 3: OS for the entire cohort and for patients stratified by treatment line

	All patients	First-line (1L)	Second-line (2L)	Third-line (3L)	Fourth-line (4L)
Number of patients, N (%)	**10,787 (100.0)**	**3,942 (36.5)**	**959 (24.3)**	**158 (4.0)**	**19 (0.5)**
Months of follow-up, mean (SD)	11.8 (16.5)	16.7 (17.8)*	12.5 (15.1)†	12.0 (15.0)‡	8.7 (10.5)#
Failures during the study period	9,628	3,221	805	132	15
Median OS, months (95% CI)	5.4 (5.2, 5.6)	10.4 (10.0, 10.7)	7.0 (6.4, 7.7)	6.9 (6.1, 7.7)	*
Survival probability after 6, 12, 24, 36 and 60 months					
6 months (95% CI)	0.47 (0.46, 0.48)	0.70 (0.68, 0.71)	0.55 (0.52, 0.58)	0.58 (0.51, 0.67)	*
12 months (95% CI)	0.29 (0.28, 0.30)	0.45 (0.43, 0.46)	0.34 (0.31, 0.37)	0.30 (0.24, 0.39)	*
24 months (95% CI)	0.16 (0.15, 0.17)	0.26 (0.24, 0.27)	0.19 (0.16, 0.21)	0.18 (0.13, 0.26)	*
36 months (95% CI)	0.12 (0.11, 0.12)	0.18 (0.17, 0.20)	0.14 (0.12, 0.17)	0.13 (0.09, 0.21)	*
60 months (95% CI)	0.08 (0.07, 0.09)	0.13 (0.12, 0.15)	0.09 (0.07, 0.12)	*	*

Asterisk means not estimable. Months of follow-up are from diagnosis*, 1L†, 2L‡, and 3L# initiation therapy to death, embarkation or end of the study.
CI, Confidence interval; OS, Overall survival; SD, Standard deviation.

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS Study Population
RESULTS Patient Outcomes 1
RESULTS Patient Outcomes 2
RESULTS Patient Outcomes 3
LIMITATIONS
APPENDIX

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

LIMITATIONS

- The study timeline spanned the COVID-19 pandemic where NHS England issued guidance to prescribe atezolizumab in the 1L setting[1]
- Pembrolizumab is not reimbursed in England
- Clinical guidelines do not endorse anti-PD-(L)1 retreatment[2,3]
- Lines of therapy were approximated via an algorithm; with a risk of misclassification

1. NHS England. NHS England interim treatment options during the COVID-19 pandemic. 2021, https://www.theacp.org.uk/userfiles/file/resources/covid_19_resources/nhs-england-interim-treatment-options-during-the-covid19-pandemic-pdf-8715724381-6-jan-2021.pdf (accessed June 2024). 2. Witjes JA, Bruins HM, Carrión A, et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2024, https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Muscle-Invasive-and-Metastatic-Bladder-Cancer-2024.pdf (accessed June 2024). 3. Powles T, Bellmunt J, Comperat E et al. Bladder cancer: ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma *Ann Oncol*. 2024;35(6):485-490.

Anti-PD-(L)1 , Anti programmed death-ligand 1; COVID, Coronavirus disease of 2019; IL, First-line; NHS, National health service.

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS Study Population
RESULTS Patient Outcomes 1
RESULTS Patient Outcomes 2
RESULTS Patient Outcomes 3
LIMITATIONS
APPENDIX

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in England: A Retrospective, Observational Study

Tinevimbo Shiri, Max Nievaart, William Perkin, Amy Zalin-Miller, Craig Knott, and Simran Gill

APPENDIX

REFERENCES

1. NHS England. NHS England interim treatment options during the COVID-19 pandemic. 2021, https://www.theacp.org.uk/userfiles/file/resources/covid_19_resources/nhs-england-interim-treatment-options-during-the-covid19-pandemic-pdf-8715724381-6-jan-2021.pdf (accessed June 2024).
2. Witjes JA, Bruins HM, Carrión A, et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2024, https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Muscle-Invasive-and-Metastatic-Bladder-Cancer-2024.pdf (accessed June 2024).
3. Powles T, Bellmunt J, Comperat E et al. Bladder cancer: ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma *Ann Oncol.* 2024;35(6):485-490.

ACKNOWLEDGMENTS:
This work uses data that has been provided by patients and collected by the NHS as part of their care and support. The datasets are collated, maintained and quality assured by the National Disease Registration Service, which is part of NHS England. Amit Kavle (SIRO Medical Writing Pvt. Ltd., India) provided graphic designing support.

FUNDING: This study was funded by Johnson & Johnson.

Presented by Simran Gill at the 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium; February 13-15, 2025; San Francisco, CA

NAVIGATION

KEY TAKEAWAY
CONCLUSIONS
INTRODUCTION
OBJECTIVES
METHODS
RESULTS
Study Population
RESULTS
Patient Outcomes 1
RESULTS
Patient Outcomes 2
RESULTS
Patient Outcomes 3
LIMITATIONS
APPENDIX